Savara Pharmaceuticals Obtains $8,600,000 Series B Funding

  • Feed Type
  • Date
    6/12/2012
  • Company Name
    Savara Pharmaceuticals
  • Mailing Address
    5900 Shepherd Mountain Cove Austin, TX 78730
  • Company Description
    Savara is a pharmaceutical company developing novel respiratory therapeutics utilizing our proprietary NanoCluster dry powder aerosol drug delivery platform.The aerosols are assembled directly from nanoparticles of an existing therapeutic and delivered via oral pulmonary or nasal routes using off-the-shelf dry powder inhalers.
  • Website
    http://www.savarapharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $8,600,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Savara will use the proceeds from this financing to advance AeroVanc (vancomycin hydrochloride inhalation powder) through a Phase IIa clinical efficacy study.
  • M&A Terms
  • Venture Investor
    Keiretsu Forum – Silicon Valley
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.